glp 1 agonist cardiovascular outcomes GLP-1 receptor agonists and outcome trials: An update glp-1 agonist clinical trials receptor

10.1016/j.neuropharm.2010.05.004 65 LaneC

Clinics prescribe 1ml weekly because it's the middle-ground safe dose, not because it's optimised for your liver's methylation capacity, your dietary methionine intake, or your current rate of fat oxidation

Subcutaneous injection may cause temporary redness and swelling

FDA approved Novo Nordisks once-daily oral GLP-1 therapy for chronic weight management, offering a pill alternative to injectable obesity treatments

Performance hinges on purity and stability

Legal Status / FDA Liraglutide is FDA-approved and legally available by prescription in the United States under two brand names: Victoza (approved January 2010): Type 2 diabetes in adults and children aged 10+, dosed at 1.2 to 1.8 mg daily Saxenda (approved December 2014): Chronic weight management in adults with BMI of 30 or greater (or 27+ with a weight-related comorbidity) and adolescents aged 12+ with obesity, dosed at 3.0 mg daily Liraglutide is not a controlled substance and is classified as a prescription medication in all major markets